ARS Pharmaceuticals, Inc. (SPRY) Reports In-Line Q2 EPS

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q2 EPS of ($0.46), in-line with the analyst estimate of ($0.46). Revenue for the quarter came in at $15.72 million versus the consensus estimate of $13.77 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
• US Defence Firm Anduril In Talks For Nissan Plant To Build Drones In Japan, Sources Say - Reuters
• Micron Technology (MU) PT Raised to $1,500 at Raymond James